- Home
- FRD vs TNXP Comparison
FRD vs TNXP Comparison
Compare FRD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- TNXP
- Stock Information
- Founded
- FRD 1965
- TNXP 2007
- Country
- FRD United States
- TNXP United States
- Employees
- FRD N/A
- TNXP N/A
- Industry
- FRD Steel/Iron Ore
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- TNXP Health Care
- Exchange
- FRD Nasdaq
- TNXP Nasdaq
- Market Cap
- FRD 122.0M
- TNXP 111.1M
- IPO Year
- FRD N/A
- TNXP N/A
- Fundamental
- Price
- FRD $17.00
- TNXP $14.90
- Analyst Decision
- FRD
- TNXP Strong Buy
- Analyst Count
- FRD 0
- TNXP 2
- Target Price
- FRD N/A
- TNXP $585.00
- AVG Volume (30 Days)
- FRD 24.4K
- TNXP 1.0M
- Earning Date
- FRD 06-10-2025
- TNXP 05-12-2025
- Dividend Yield
- FRD 0.94%
- TNXP N/A
- EPS Growth
- FRD N/A
- TNXP N/A
- EPS
- FRD 0.81
- TNXP N/A
- Revenue
- FRD $447,616,000.00
- TNXP $10,094,000.00
- Revenue This Year
- FRD N/A
- TNXP $12.17
- Revenue Next Year
- FRD N/A
- TNXP $789.15
- P/E Ratio
- FRD $20.62
- TNXP N/A
- Revenue Growth
- FRD N/A
- TNXP 29.94
- 52 Week Low
- FRD $12.24
- TNXP $6.76
- 52 Week High
- FRD $19.47
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- FRD 61.76
- TNXP 42.54
- Support Level
- FRD $14.26
- TNXP $14.33
- Resistance Level
- FRD $17.24
- TNXP $22.25
- Average True Range (ATR)
- FRD 1.02
- TNXP 1.88
- MACD
- FRD 0.31
- TNXP -0.55
- Stochastic Oscillator
- FRD 95.20
- TNXP 5.83
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.